Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled,
4 hours ago
- #mycophenolate mofetil
- #nephrotic syndrome
- #prednisone
- The INTENT trial compared mycophenolate mofetil (MMF) with prednisone for initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children.
- MMF was found to be non-inferior to prednisone in preventing treated relapses over 24 months.
- MMF treatment resulted in fewer glucocorticoid-related side effects, such as arterial hypertension, lower BMI, and fewer psychological abnormalities.
- However, MMF was associated with a higher incidence of infections compared to prednisone.
- The study suggests MMF could be a viable alternative to prednisone, reducing glucocorticoid-related toxic effects.
- The trial was a phase 3, multicentre, open-label, randomised, controlled study conducted in Germany.
- Funding was provided by the German Federal Ministry of Education and Research.